A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia

A 24-week, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia

Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.

This study is not recruiting in the United States.

Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.

Inclusion Criteria:

• Diagnosed as schizophrenia
• Not responded to at least two atypical antipshychotics launched in Japan
• Inpatient

Exclusion Criteria:

• Low white blood cell count
• Significant heart diseases
• Diabetes mellitus

Other protocol-defined exclusion criteria may apply.